Biotech Values

[DewDiligence]

VRTX—(-11%/AH)—reports phase-2 failure in acute pain:

https://www.businesswire.com/news/home/20250804247622/en/Vertex-Announces-Results-from-Phase-2-Study-of-VX-993-for-the-Treatment-of-Acute-Pain

Vertex Pharmaceuticals Incorporated today announced topline results from its recently completed Phase 2, randomized, double-blind, placebo-controlled dose-ranging study evaluating the safety and efficacy of its investigational selective NaV1.8 pain signal inhibitor, VX-993, in treating acute pain after bunionectomy surgery. Treatment with VX-993 did not result in a statistically significant improvement on the primary endpoint of the time-weighted Sum of the Pain Intensity Difference from 0 to 48 hours (SPID48) compared to placebo.

Based on these results, Vertex will not progress VX-993 into pivotal development as monotherapy in acute pain.